- Page 1: Defining Phenotypes: Expanding Our
- Page 5 and 6: Asthma Phenotype Task Force Goal Co
- Page 7 and 8: Asthma Phenotypes • Define 9 phen
- Page 9 and 10: Asthma Phenotypes • Define 9 phen
- Page 11 and 12: Allergic Proposed Definition • Se
- Page 13 and 14: Allergic Asthma: Clinical Informati
- Page 15 and 16: Non-Allergic Asthma Background •
- Page 17 and 18: Non-Allergic Asthma: Demographic an
- Page 19 and 20: Aspirin-Exacerbated Respiratory Dis
- Page 21 and 22: AERD Task Force Proposed Definition
- Page 23 and 24: AERD Genetics 1. Familial cases rep
- Page 25 and 26: AERD Clinical Features (cont’d) 4
- Page 27 and 28: Infection-Induced Asthma: Definitio
- Page 29 and 30: Infection-Induced Asthma: Histopath
- Page 31 and 32: Background Exercise-Induced Asthma
- Page 33 and 34: Exercise-Induced Bronchospasm: Defi
- Page 35 and 36: Clinical Characteristics • EIB oc
- Page 37 and 38: Background on Pre-Asthma Wheezing i
- Page 39 and 40: Pre-Asthma Wheezing in Infants and
- Page 41 and 42: Pre-Asthma Wheezing in Infants and
- Page 43 and 44: Asthma Phenotypes - Clinical presen
- Page 45 and 46: Background Exacerbation Prone Asthm
- Page 47 and 48: Definition Exacerbation Prone Asthm
- Page 49 and 50: Background Irreversible Airflow Lim
- Page 51 and 52: Irreversible Airflow Limitation in
- Page 53 and 54:
Background Eosinophilic Asthma: Ass
- Page 55 and 56:
Asthma Phenotypes - Clinical presen
- Page 57 and 58:
Definition Neutrophilic Asthma Intr
- Page 59 and 60:
Asthma Phenotypes Task Force Nation
- Page 61 and 62:
Summary: Asthma Phenotype Definitio
- Page 63 and 64:
Haldar P et al. Am J Respir Crit Ca
- Page 66:
Asthma: Challenges in Treating a He
- Page 69 and 70:
Asthma Is Prevalent: Significant Mo
- Page 71 and 72:
Asthma Phenotype Task Force NHLBI,
- Page 73 and 74:
Asthma Phenotype Task Force Goal Co
- Page 75 and 76:
Asthma Phenotypes • Define 9 phen
- Page 77 and 78:
Co-Morbid Conditions which Complica
- Page 79 and 80:
6. Osteopenia and Osteoporosis 7. P
- Page 82 and 83:
Asthma • Historical Definition: -
- Page 84 and 85:
Airway Inflammation • Also caused
- Page 86 and 87:
Early Phase Reaction (EPR) Occurs W
- Page 88 and 89:
Short and long-acting beta-2 agonis
- Page 90 and 91:
Short and long-acting beta-2 agonis
- Page 92 and 93:
Inhaled Corticosteroids (ICS)
- Page 94 and 95:
Inhaled Corticosteroids (ICS) • S
- Page 96 and 97:
GC Resistance in Asthma: • Defini
- Page 98 and 99:
Leukotriene Modifiers • Strengths
- Page 100 and 101:
Theophylline • Limitations: - Inf
- Page 102 and 103:
Omalizumab • FDA-approved for pat
- Page 104 and 105:
Omalizumab (Cochrane Database) •
- Page 106 and 107:
Allergen Immunotherapy - Allergen i
- Page 108 and 109:
Asthma Assessment and Monitoring: K
- Page 110:
Assessing Asthma Severity: Risk Dom
- Page 114:
Categories of Evidence Used to Supp
- Page 117:
Estimated Comparative Daily Dosages
- Page 121:
Estimated Comparative Daily Dosages
- Page 125:
Estimated Comparative Daily Dosages
- Page 128 and 129:
Conclusions • Severity, control,